ClinicalTrials.gg
RecruitingNCT06569615Updated Nov 16, 2026

Efficacy of Extracorporeal Shock Wave Therapy, LASER Therapy and Cryotherapy in Patients Having Sacroiliitis

An interventional study of shock wave therapy and LASER Therapy in Sacroilitis, sponsored by Najran University. Recruiting at 1 site in Saudi Arabia. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Najran University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Study summary

This research aimed to determine the effect of extracorporeal shock wave therapy, LASER therapy and cryotherapy on PPT, Pain and functional disability in patients having Sacroiliitis.

Read the detailed description

The study will be based on a three-arm parallel group randomized control design. sixty participants of sacroiliitis will be recruited from the Physiotherapy department, at Najran University, K.S.A. Study objectives and procedure will be properly explained and written informed consent will be obtained at the beginning of the study. All the participants will be randomly divided into three groups 1, 2 and 3.

All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.

From the 2nd week:

Group 1 will be administered ESWT plus exercise, Group 2 will be administered LASER plus exercise, and Group 3 will be administered cryotherapy and exercise.

02

Conditions studied

  • Sacroilitis
03

In context

Lead sponsor

Najran University is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pain in one or both buttocks, hip pain, thigh pain, or even pain more distal.
  • Patients may report that their pain is worse after sitting for prolonged periods or with rotational movements that will be intensified when bending laterally or backward and
  • Positive outcome in a minimum of three out of five pain-provocation tests (i.e., compression test, distraction test, Faber sign, Gaenslen test, and thigh thrust.
  • Pain close to the posterior superior iliac spine and the patient could point with a single finger to the location of pain (Fortin Finger Test).

Exclusion criteria

Exclusion Criteria:

  • The Participant who had undergone surgery or experienced significant trauma to the spine, pelvis, lower limb, chest, or abdomen within the past 12 months.
  • The participants with lower extremity musculoskeletal disorders, localized spinal pathology, congenital anomalies of the hip, pelvis, or spine that limited mobility.
  • having a positive straight leg raising test
  • receiving nonsteroidal anti-inflammatory drugs, hormonal therapy, or injections
  • individuals with tumors, fractures. ankylosing spondylitis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group 1

    shock wave Group

    Other: shock wave therapy · Other: Exercises

  • Experimental
    Group 2

    LASER Group

    Other: LASER Therapy · Other: Exercises

  • Experimental
    Group 3

    Cryotherapy Group

    Other: Cryotherapy · Other: Exercises

Interventions

  • Othershock wave therapy

    All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week. From the 2nd week: Participants will be given Radial shockwave therapy, (Storz Medical Shock Master MP200 device) for 10 minutes/session, one session/week, for 8 weeks.

  • OtherLASER Therapy

    All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week. From the 2nd week: Participants will be given LASER, (LEVELASER EZ1 EASYONE) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks.

  • OtherCryotherapy

    All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week. From the 2nd week: Participants will be given Cryotherapy, (Gymna UniphyCryoflow 1000 IR Shock Master ICE-CT device) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks.

  • OtherExercises

    The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.

06

What researchers measure

Primary outcomes

  1. Pain Pressure Threshold (PPT)

    Pain pressure threshold of muscle tenderness will be measured by using the algometer

    Time frame: 8 Weeks

  2. Pain Intensity

    Pain intensity will be measured by using the Visual Analogue Scale (VAS),a linear scale wherein patients indicate their pain intensity on a 10 cm line ranging from 'no pain' to 'worst imaginable pain'

    Time frame: 8 Weeks

Secondary outcomes

  1. Functional Disability

    Functional disability will be measured by using the Oswestry Disability Index (ODI),a validated 10-item questionnaire evaluating various dimensions of daily living

    Time frame: 8 Weeks

07

Study locations

1 of 1 sites recruiting
  • Hashim Ahmed
    Najran, Najran Region 1988, Saudi Arabia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 26, 2024
StartActual
Aug 27, 2024
Primary completionEst.
Dec 10, 2026was Sep 2026
CompletionEst.
Dec 10, 2026was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 10, 2026→Dec 10, 2026
Nov 16, 2026
Study completion
Sep 10, 2026→Dec 10, 2026
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Sep 10, 2026→Dec 10, 2026
    Study completion Sep 10, 2026→Dec 10, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06569615
Lead sponsor
Najran University
Responsible party
Hashim Ahmed (Assistant Professor, Najran University) — Principal investigator
First posted
Aug 26, 2024
Start date
Aug 27, 2024
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Hashim Ahmed, PhD
Contact
hahasan@nu.edu.sa
+966507589062
Hashim Ahmed, PhD
principal investigator · Assistant Professor

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion